OBJECTIVE: To investigate the effect of human growth hormone (GH) injections on growth velocity in growth-impaired children with Crohn's disease (CD). STUDY DESIGN: Ten children and adolescents (mean age, 12.6 +/- 4.5 years; 6 males) with CD and poor height growth were treated with open-label recombinant GH, 0.043 mg/kg/day administered via subcutaneous injection, for 1 year. Patients were retrospectively matched with untreated patients (3 comparisons per case) by race, age, sex, and baseline height. Primary endpoint was height velocity; secondary endpoints were disease activity, body composition, and bone density determined by dual-energy x-ray absorptiometry scan. RESULTS: Mean height velocity increased by 5.33 +/- 3.40 (mean +/- standard deviation) cm/year in the GH-treated patients during the year of GH treatment, compared with 0.96 +/- 3.52 cm/year in the comparison group (P = .03). Height z-score increased by 0.76 +/- 0.38 in the treated group, compared with 0.16 +/- 0.40 in the comparison group (P < .01), and weight z-score increased by 0.81 +/- 0.89 in the treated group, compared with 0.00 +/- 0.57 in the comparison group (P < .01). Bone density revealed an increase of 0.31 +/- 0.33 in the lumbar spine z-score (P = .03 vs baseline). CONCLUSIONS: GH treatment increases height velocity and may enhance bone mineralization in children with CD. A randomized controlled trial in a large cohort of children is needed to evaluate the ultimate impact of GH treatment.
OBJECTIVE: To investigate the effect of humangrowth hormone (GH) injections on growth velocity in growth-impaired children with Crohn's disease (CD). STUDY DESIGN: Ten children and adolescents (mean age, 12.6 +/- 4.5 years; 6 males) with CD and poor height growth were treated with open-label recombinant GH, 0.043 mg/kg/day administered via subcutaneous injection, for 1 year. Patients were retrospectively matched with untreated patients (3 comparisons per case) by race, age, sex, and baseline height. Primary endpoint was height velocity; secondary endpoints were disease activity, body composition, and bone density determined by dual-energy x-ray absorptiometry scan. RESULTS: Mean height velocity increased by 5.33 +/- 3.40 (mean +/- standard deviation) cm/year in the GH-treated patients during the year of GH treatment, compared with 0.96 +/- 3.52 cm/year in the comparison group (P = .03). Height z-score increased by 0.76 +/- 0.38 in the treated group, compared with 0.16 +/- 0.40 in the comparison group (P < .01), and weight z-score increased by 0.81 +/- 0.89 in the treated group, compared with 0.00 +/- 0.57 in the comparison group (P < .01). Bone density revealed an increase of 0.31 +/- 0.33 in the lumbar spine z-score (P = .03 vs baseline). CONCLUSIONS: GH treatment increases height velocity and may enhance bone mineralization in children with CD. A randomized controlled trial in a large cohort of children is needed to evaluate the ultimate impact of GH treatment.
Authors: J S Hyams; F Mandel; G D Ferry; J D Gryboski; P M Kibort; B S Kirschner; A M Griffiths; A J Katz; J T Boyle Journal: J Pediatr Gastroenterol Nutr Date: 1992-02 Impact factor: 2.839
Authors: Nelly Mauras; Donald George; Jonathan Evans; David Milov; Steven Abrams; Annie Rini; Susan Welch; Morey W Haymond Journal: Metabolism Date: 2002-01 Impact factor: 8.694
Authors: Lee A Denson; Mi-Ok Kim; Ramona Bezold; Rebecca Carey; Bankole Osuntokun; Cade Nylund; Tara Willson; Erin Bonkowski; Dandan Li; Edgar Ballard; Margaret Collins; M Susan Moyer; David J Klein Journal: J Pediatr Gastroenterol Nutr Date: 2010-08 Impact factor: 2.839
Authors: Jessica J Lee; Jonah B Essers; Subra Kugathasan; Johanna C Escher; Guillaume Lettre; Johannah L Butler; Michael C Stephens; Marco F Ramoni; Richard J Grand; Joel Hirschhorn Journal: Ann Hum Genet Date: 2010-09-15 Impact factor: 1.670
Authors: Robert M Flight; Benjamin J Harrison; Fahim Mohammad; Mary B Bunge; Lawrence D F Moon; Jeffrey C Petruska; Eric C Rouchka Journal: Front Genet Date: 2014-04-29 Impact factor: 4.599
Authors: Mabrouka A Altowati; Ashley P Jones; Helen Hickey; Paula R Williamson; Farah M Barakat; Nicolene C Plaatjies; Ben Hardwick; Richard K Russell; Thomas Jaki; S Faisal Ahmed; Ian R Sanderson Journal: Pilot Feasibility Stud Date: 2016-12-05